The efficacy of PD-1/PD-L1 inhibitors, as promising immunotherapeutic agents, was analyzed by Chen et al. in a meta-analysis based on 91 published clinical trials, phases I to III, in different cancer types, including gynecological cancers. Here, PDCD1 is linked to cancer.